COAGULATION


same nominal difference was noted from abnormal to normal on APTT assay with sthemO CK Prest (P=0.01), with the normal APTT moving from 27.5 to 27.8 seconds.


Pontis attributes this to being ‘due to the very high precision of the device’. The statistical relevance of such a low difference would be consistent with assay precision results.


Increasing overall productivity Mr Querel points out that, alongside dual technology and chemiluminescence, the sthemO incorporates a range of other functionality innovations that will help NHS laboratories achieve greater efficiency. Other productivity innovations include: n Continuous loading for samples, reagents and consumables - supporting high productivity


n Onboard cuvette capacity of 1920, reducing fill time


n Novel time-saving cuvette and rotor design with four technologies in one (VBDS, optical, immunoturbidimetric, chemiluminescence) supporting high throughput


n Automatic tube type recognition sensing correct levels, without needing manual checks or intervention


n Enhanced software with embedded accreditation tools


n Clinical decision support including diagnostic algorithms


n Automatic reagent stirring to remove potential errors


n Pre-calibration and improved calibration curve management


n Error-free solution with onboard management of reagent stability with automatic download of reagent information


n New data management system - sthemE manager.


The analyser has been designed to be easy to use by any member of staff, requiring just two hours training. Both the sthemO 301 and 201 will share the same hardware and software so whichever system is in place, and wherever staff are rotated across a hospital network, they will be familiar with it.


Numerous multicentre evaluation studies are being carried out in the UK and Europe on the new sthemO 301 analyser, with some early findings already presented as posters.


Gold standard in haemostasis Stago has grown exponentially in the UK from its opening less than 20 years ago. It rose to the recent challenge of COVID-19, meeting the increased demand for D-Dimer testing as well as supporting laboratories with its remote trouble- shooting support. Over the last two years, it has reported its best ever performance. Progress started to accelerate 10 years ago with the changes demanded by NHS restructuring. The excellence of Stago’s reagents and its instrumentation performance and reliability provided individual trusts and managed service partners with the tools to meet these challenges.


This included the company’s reputation for highly efficient engineering support, flexible and approachable staff, and the company’s skill at remote troubleshooting to minimise downtime. “We have focused on consistently providing instruments and assay quality that support laboratories as they face greater workload pressures while having to achieve cost saving,” explained Mr Querel. Research and development (R&D)


underpin its success, with Stago technologies seen as setting the ‘gold standard’ for scientific excellence in haemostasis. It is one of the few companies in the world that has developed its in-house R&D capability to be able to design, develop and manufacture its own haemostasis reagents, consumables and analysers. The sthemO 301 continues this tradition, offering NHS laboratories the increased productivity and efficiency required to deliver a modern pathology service.


References 1 Pontis A, Delanoe M, Schilliger N et al.


A performance evaluation of sthemO 301 coagulation analyzer and associated reagents. J Clin Lab Anal. 2023;37(11- 12):e24929. doi:10.1002/jcla.24929


3 Clinical and Laboratory Standards Institute. H21-A5. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays, 5th Edn. CLSI 2008 (https://clsi.org/media/1399/ h21a5_sample.pdf)


For laboratories with different throughput requirements or where space for expansion may be restricted, a benchtop model, the sthemO 201, will be available early in 2024. This will offer the same efficiency and analytical performance


7


3 Woolley A, Golmard JL, Kitchen S. Effects of haemolysis, icterus and lipaemia on coagulation tests as performed on Stago STA-Compact-Max analyser. Int J Lab Hematol. 2016;38(4):375-388. doi:10.1111/ijlh.12498


For further information, visit Stago at stand 619 at the IBMS Congress, or visit the website.


https://sthemo.stago.com SEPTEMBER 2023 WWW.PATHOLOGYINPRACTICE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41